A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Trial Profile

A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Bendamustine (Primary) ; Gemcitabine (Primary) ; Ibrutinib (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary) ; TAK 659 (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 02 May 2017 Planned End Date changed from 1 Aug 2018 to 26 Apr 2019.
    • 02 May 2017 Planned primary completion date changed from 1 Aug 2018 to 26 Apr 2019.
    • 02 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top